NCT07024784View on ClinicalTrials.gov

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

PHASE2RecruitingINTERVENTIONAL
Enrollment

377

Participants

Timeline

Start Date

July 30, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

February 29, 2028

Conditions
Gynecologic CancersPlatinum-Sensitive Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer (PSOC)
Interventions
DRUG

IMGN151

Intravenous (IV) infusion

DRUG

Carboplatin

Intravenous (IV) infusion

DRUG

Bevacizumab

Intravenous (IV) infusion

DRUG

Olaparib

Oral Tablet

Trial Locations (4)

3525408

RECRUITING

Rambam Health Care Campus /ID# 276004, Haifa

5265601

RECRUITING

The Chaim Sheba Medical Center /ID# 275997, Ramat Gan

6423906

RECRUITING

Tel Aviv Sourasky Medical Center /ID# 275852, Tel Aviv

9103102

RECRUITING

Shaare Zedek Medical Center /ID# 275854, Jerusalem

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY